No. 3969 August 23, 2019 and CSO that the Kaspars have not been involved in the Novartis subsidiary’s op- erations since early May. Asked whether more AveXis employees will exit the company due to the preclini- cal safety data manipulation revealed on 6 August or whether other actions will be taken by Novartis in relation to the matter, Althoff told Scrip: “We cannot comment on the specifics of who is involved, but we can confirm this issue was not widespread, ei- ther in our overall dataset nor in our com- pany or any function within our company and was limited to a few individuals.” Novartis CEO Vas Narasimhan said in a 7 August conference call about the Zol- gensma data controversy that the compa- ny was in the process of “exiting the small number of AveXis scientists involved” in the data manipulation, which occurred Novartis Swaps Two AveXis before Novartis bought the gene therapy firm. (Also see “Novartis CEO Explains De- lay In Telling US FDA About Zolgensma Executives For One Following Data Fraud: We Wanted To Understand It First” - Pink Sheet, 7 Aug, 2019.) Zolgensma Data Manipulation Novartis acquired AveXis for $8.7bn MANDY JACKSON
[email protected] last year. (Also see “Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisi- ovartis AG said when it disclosed the Zolgensma BLA was manipulated. Page tion” - Scrip, 9 Apr, 2018.) Zolgensma was that preclinical safety data for Zol- Bouchard, whose most recent function was the lead asset in AveXis’s R&D pipeline and Ngensma were manipulated in the bi- global head of preclinical safety for Novar- won US Food and Drug Administration ologic license application for the gene ther- tis Institutes of Biomedical Research (NIBR), approval in May, becoming the world’s apy that the company would be “exiting” was named senior vice president and chief most expensive drug with a $2m list price.